saypha ChiQ
Croma-Pharma GmbH · Decision date Oct 7, 2026
What did the FDA approve?
This record is a PMA supplement, not a new approval of the whole device. It is supplement S001 to P250021, filed under the Normal 180 Day Track No User Fee pathway with reason "Postapproval Study Protocol." The stated decision is approval of "the scale validation protocol for the post-approval study (PAS)." That wording points to a protocol governing validation of a scale used in a post-approval study; the entry does not describe the scale, the validation approach, or what the study will measure.
The original PMA scope is captured only as product code LMH, "Implant, dermal, for aesthetic use," under General, Plastic Surgery, with applicant Croma-Pharma GmbH. Because the identifier shares the P250021 root, this supplement sits within that original PMA rather than establishing a separate approval. The quoted statement reports the agency's approval of a protocol; it is not evidence of safety, clinical effectiveness, or a new indication. Specifics on endpoints, sample size, and validation criteria are absent.
FDA approval order statement
Approval of the scale validation protocol for the post-approval study (PAS) referenced above
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 7, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250021/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Oct 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250021 · Original PMA
saypha ChiQ
P250021/S001 received
Application receipt date recorded by FDA.
P250021/S001 · FDA decision
Normal 180 Day Track No User Fee
P250021/S002 · Related supplement
saypha ChiQ
Timeline entries are records held by MedtechLedger for P250021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
saypha ChiQP250021 | Croma-Pharma GmbH | PMA approval | Jun 12, 2026 | FDA |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
Restylane ContourP140029/S058 | Q-Med AB | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Croma-Pharma GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Industriezeile 6, Leobendorf, 2100
Sources and methodology
- Original FDA record: P250021/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




